These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34147517)

  • 81. Prediction of the Synergistic Glass Transition Temperature of Coamorphous Molecular Glasses Using Activity Coefficient Models.
    Zhao X; Cheng S; Koh YP; Kelly BD; McKenna GB; Simon SL
    Mol Pharm; 2021 Sep; 18(9):3439-3451. PubMed ID: 34313449
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Preparation and characterization of co-amorphous Ritonavir-Indomethacin systems by solvent evaporation technique: improved dissolution behavior and physical stability without evidence of intermolecular interactions.
    Dengale SJ; Ranjan OP; Hussen SS; Krishna BS; Musmade PB; Gautham Shenoy G; Bhat K
    Eur J Pharm Sci; 2014 Oct; 62():57-64. PubMed ID: 24878386
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Amorphous solid dispersion with increased gastric solubility in tandem with oral disintegrating tablets: a successful approach to improve the bioavailability of atorvastatin.
    Salmani JM; Lv H; Asghar S; Zhou J
    Pharm Dev Technol; 2015 Jun; 20(4):465-72. PubMed ID: 24490758
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers.
    Dhumal RS; Shimpi SL; Paradkar AR
    Acta Pharm; 2007 Sep; 57(3):287-300. PubMed ID: 17878109
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Moisture-Induced Amorphous Phase Separation of Amorphous Solid Dispersions: Molecular Mechanism, Microstructure, and Its Impact on Dissolution Performance.
    Chen H; Pui Y; Liu C; Chen Z; Su CC; Hageman M; Hussain M; Haskell R; Stefanski K; Foster K; Gudmundsson O; Qian F
    J Pharm Sci; 2018 Jan; 107(1):317-326. PubMed ID: 29107047
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Pharmaceutical development of an amorphous solid dispersion formulation of elacridar hydrochloride for proof-of-concept clinical studies.
    Sawicki E; Schellens JH; Beijnen JH; Nuijen B
    Drug Dev Ind Pharm; 2017 Apr; 43(4):584-594. PubMed ID: 28010129
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Dissolution enhancement of tadalafil by liquisolid technique.
    Lu M; Xing H; Yang T; Yu J; Yang Z; Sun Y; Ding P
    Pharm Dev Technol; 2017 Feb; 22(1):77-89. PubMed ID: 27268461
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Solid state properties and drug release behavior of co-amorphous indomethacin-arginine tablets coated with Kollicoat® Protect.
    Petry I; Löbmann K; Grohganz H; Rades T; Leopold CS
    Eur J Pharm Biopharm; 2017 Oct; 119():150-160. PubMed ID: 28602869
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Elucidation of Compression-Induced Surface Crystallization in Amorphous Tablets Using Sum Frequency Generation (SFG) Microscopy.
    Mah PT; Novakovic D; Saarinen J; Van Landeghem S; Peltonen L; Laaksonen T; Isomäki A; Strachan CJ
    Pharm Res; 2017 May; 34(5):957-970. PubMed ID: 27738954
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Release of poorly soluble drugs from HPMC tablets studied by FTIR imaging and flow-through dissolution tests.
    van der Weerd J; Kazarian SG
    J Pharm Sci; 2005 Sep; 94(9):2096-109. PubMed ID: 16052556
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Design, optimization, preparation and evaluation of dispersion granules of valsartan and formulation into tablets.
    Shrivastava AR; Ursekar B; Kapadia CJ
    Curr Drug Deliv; 2009 Jan; 6(1):28-37. PubMed ID: 19418953
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Characterization of physical mixtures and directly compressed tablets of sulfamerazine polymorphs: implications on in vitro release characteristics.
    Roy S; Alexander KS; Riga AT; Chatterjee K
    J Pharm Sci; 2003 Apr; 92(4):747-59. PubMed ID: 12661061
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Variation concentration effect of propyleneglycol, glycerin, and polyethyleneglycol 400 to physical properties and dissolution rate of loratadine liquisolid tablet.
    Eryani MC; Hendradi E; Siswandono
    J Basic Clin Physiol Pharmacol; 2021 Jun; 32(4):583-587. PubMed ID: 34214337
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Determination of the Optimal Molar Ratio in Amino Acid-Based Coamorphous Systems.
    Liu J; Rades T; Grohganz H
    Mol Pharm; 2020 Apr; 17(4):1335-1342. PubMed ID: 32119557
    [TBL] [Abstract][Full Text] [Related]  

  • 95. 3D-printed tablets using a single-step hot-melt pneumatic process for poorly soluble drugs.
    Kim SJ; Lee JC; Ko JY; Lee SH; Kim NA; Jeong SH
    Int J Pharm; 2021 Feb; 595():120257. PubMed ID: 33486029
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Inhibiting Surface Crystallization and Improving Dissolution of Amorphous Loratadine by Dextran Sulfate Nanocoating.
    Zeng A; Yao X; Gui Y; Li Y; Jones KJ; Yu L
    J Pharm Sci; 2019 Jul; 108(7):2391-2396. PubMed ID: 30831122
    [TBL] [Abstract][Full Text] [Related]  

  • 97. The development of carbamazepine-succinic acid cocrystal tablet formulations with improved in vitro and in vivo performance.
    Ullah M; Hussain I; Sun CC
    Drug Dev Ind Pharm; 2016; 42(6):969-76. PubMed ID: 26460090
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Design of Ternary Amorphous Solid Dispersions for Enhanced Dissolution of Drug Combinations.
    Li J; Duggirala NK; Kumar NSK; Su Y; Suryanarayanan R
    Mol Pharm; 2022 Aug; 19(8):2950-2961. PubMed ID: 35797094
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Preparation and evaluation of solid dispersions of piroxicam and Eudragit S100 by spherical crystallization technique.
    Maghsoodi M; Sadeghpoor F
    Drug Dev Ind Pharm; 2010 Aug; 36(8):917-25. PubMed ID: 20180658
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Spatial Distribution of Trehalose Dihydrate Crystallization in Tablets by X-ray Diffractometry.
    Thakral NK; Yamada H; Stephenson GA; Suryanarayanan R
    Mol Pharm; 2015 Oct; 12(10):3766-75. PubMed ID: 26332906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.